Thus, physicians should still consider the potential risks of acute nephritis and renal failure in administering GLP‐1 RAs, particularly for individuals with uncontrolled T2D, polyuria, polydipsia, or those prone to volume depletion.35, 37, 38, 39. The gene discussed is GLP1R; the disease is Polydipsia.